We believe the tools to develop cures for neurodegenerative diseases are on the horizon. Our care model removes barriers to advancing these cures—from diagnosis to clinical trials and research.
Scaled disease populations for robust research
Specialist-led care models for precision insights
Focus on fast access and comprehensive diagnostics
Engaged patient populations actively participating in care
We remove barriers to advancing cures by scaling disease populations, leveraging specialist-led care models, and providing fast diagnostics and engaged patient populations.
Patient-derived 3D brain models that faithfully recapitulate disease features, allowing our lab to screen promising therapeutics
Proprietary cell models viable for new target discovery, target validation, and translational data generation
50-state, rapidly enrolled Expanded Access programs
Highly accessible patient engagement systems
FDA-grade data collection and management
Fully functional decentralized trial site operations
Comprehensive support for recruitment, study assessments, in-home sample collection and more
Access point for patients to engage with disease specialists and understand treatment options
Detailed insights and analytics to understand access, barriers and patient needs
Track real-world care patterns across geographies and payers
Identify friction points in diagnosis, referral, and treatment initiation
Deeply phenotyped and diverse patient population
Rapid enrollment through engaged clinicians across all 50 states
Standardized clinical assessments and biosample collection at scale
High-fidelity retrospective population analysis; outcomes data for publication
Longitudinal EMR data spanning early symptoms to long-term outcomes
Rich data across demographics, comorbidities, and treatment patterns
If you’re interested in discussing opportunities with our team or would like to connect at upcoming events, please contact us.
